Evaluating the efficacy of tissue-engineered human amniotic membrane in the treatment of myocardial infarction

Regen Med. 2019 Feb;14(2):113-126. doi: 10.2217/rme-2018-0024. Epub 2019 Feb 11.

Abstract

Aim: The aim of this study was to evaluate the efficacy of tissue-engineered amniotic membrane (AM) in the treatment of myocardial infarction lesions.

Materials & methods: 20 rats were subjected to coronary arterial ligation in order to induce myocardial infarction injury. Decellularized human AMs were seeded with 2 × 105 adipose-derived mesenchymal stem cells and were implanted in the infarcted hearts.

Results & conclusion: Histological and immunohistochemical evaluations indicated the regeneration of cardiomyocytes and reduction of inflammation and fibrosis in the patch-implanted group compared with a control group, 14 days after the surgery. Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate biotin nick-end labeling assay was suggestive for apoptosis reduction in the patch-implanted specimens. This study suggested that human AM can be developed into a novel treatment for treating postmyocardial infarction.

Keywords: adipose-derived mesenchymal stem cells; amniotic membrane; angiogenesis; cardiac patch; cardiomyocyte regeneration; left anterior descending; myocardial infarction; regenerative medicine; stem cell therapy; tissue engineering.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amnion / cytology
  • Amnion / transplantation*
  • Animals
  • Apoptosis
  • Humans
  • Myocardial Infarction / pathology
  • Myocardial Infarction / surgery*
  • Myocytes, Cardiac / pathology
  • Rats
  • Regenerative Medicine / methods
  • Tissue Engineering / methods